| Literature DB >> 15364067 |
Abstract
The convergence of genomic technologies and the development of drugs designed against specific molecular targets provides many opportunities for using bioinformatics to bridge the gap between biological knowledge and clinical therapy. Identifying genes that have properties similar to known targets is conceptually straightforward. Additionally, genes can be linked to cancer via recurrent genomic or genetic abnormalities. Finally, by integrating large and disparate datasets, gene-level distinctions can be made between the different biological states that the data represents. These bioinformatics approaches and their associated methodologies, which can be applied across a range of technologies, facilitate the rapid identification of new target leads for further experimental validation.Entities:
Mesh:
Year: 2004 PMID: 15364067 DOI: 10.1016/S1359-6446(04)03224-6
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851